CONMED Corporation (NDAQ:CNMD) had its target bumped up to $54.00 by Needham in an issued report announced Thursday April 27, 2017. The bumped up target suggests a potential upside of 0.09% based on the company's last stock close price.
Just yesterday CONMED Corporation (NDAQ:CNMD) traded 1.97% higher at $49.47. The company’s 50-day average is $43.95 and its two hundred day average is $43.21. With the last close up 11.39% relative to the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.02% over the date range. Volume of trade was up over the average, with 230,934 shares of CNMD changing hands over the typical 169,055
See Chart Below
CONMED Corporation has 52 week low of $37.60 and a one year high of $50.16 with a price-earnings ratio of 92.56 and has a total market value of $0.
A total of 5 equity analysts have released a ratings update on CNMD. Two equity analysts rating the company a strong buy, two equity analysts rating the stock a buy, 3 firms rating the stock a hold, zero brokerages rating the company a underperform, and finally zero brokerages rating the stock a sell with a average stock price target of $45.80.
Brief Synopsis On CONMED Corporation (NDAQ:CNMD)
CONMED Corporation is a medical technology company. The Company is engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. The Company provides surgical devices and equipment for minimally invasive procedures. The Company's products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology. The Company's product lines consist of orthopedic surgery, general surgery and surgical visualization. As of December 31, 2016, the Company's products are distributed domestically directly to over 6,000 hospitals, surgery centers and other healthcare institutions, as well as through medical specialty distributors. The Company's orthopedic surgery product lines include sports medicine, powered surgical instruments, and sports biologics and tissue. These products are marketed under a range of brands, including Hall, CONMED Linvatec, Concept and Shutt.
The post CONMED Corporation (NDAQ:CNMD) stock price target raised to $54.00, issued a report today by Needham appeared first on Octafinance.